Dry-powder inhaler

A dry-powder inhaler (DPI) is a device that aerosolizes drugs into fine powders, which are then inhaled directly into the lungs for local or systemic effects. DPIs are commonly used due to their ease of use, portability, ability to deliver high drug masses, and low cost. They are used for deep lung deposition and offer satisfactory pulmonary deposition via patient respiration.From: Nanoparticles in Life Sciences and Biomedicine [2018], Influence of microbubbles on the production of spray-dried inhalable particles [2022], Supercritical Fluid Technology in Materials Science and Engineering [2018]

New Approaches from Nanomedicine and Pulmonary Drug Delivery for the Treatment of Tuberculosis

View Chapter

Purchase Book

Published in Ana Rute Neves, Salette Reis, Nanoparticles in Life Sciences and Biomedicine, 2018

Joana Magalhães, Alexandre C. Vieira, Soraia Pinto, Sara Pinheiro, Andreia Granja, Susana Santos, Marina Pinheiro, Salette Reis

The aerosolization of drugs as fine powders using dry powder inhalers (DPIs) is a convenient way of delivering drugs to the lungs. Liquid formulations can also be administered through a nebulizer. Alternatively, drugs can be directly delivered to the lungs, without prior aerosolization, using an insufflator [52].

Influence of microbubbles on the production of spray-dried inhalable particles

View Article

Journal Information

Published in Drying Technology, 2022

Loreana Gallo, Marcos Andrés Serain, Carlos Renaudo, Eduardo López, Verónica Bucalá

The administration of drugs through the pulmonary route is becoming relevant for the treatment of lung and systemic diseases by using appropriate inhalers.[1] Among them, dry powder inhalers (DPIs) are the most commonly employed devices because they offers several advantages over other inhalation techniques, such as: ease of use, convenient portability, satisfactory pulmonary deposition via the patient respiration, easy incorporation of high mass of drugs, adequate physicochemical stability and low cost.[2] In addition, DPIs as propellant-free devices produce ten times less greenhouse effect than pressurized metered dose inhalers (propellant-driven technology).[3] The DPIs market begins in the 1960s and the adoption by pharmaceutical companies has been growing steadily due to the inhalers advantages. The DPIs market size exceeded US$16 billion in 2015 and is expected to continue growing at 5% CAGR (compound annual growth rate) until 2024.[4]

Dry-powder inhaler

Explore chapters and articles related to this topic

New Approaches from Nanomedicine and Pulmonary Drug Delivery for the Treatment of Tuberculosis

Influence of microbubbles on the production of spray-dried inhalable particles